Unspecified cholesteatoma, bilateral
ICD-10 H71.93 is a billable code used to indicate a diagnosis of unspecified cholesteatoma, bilateral.
Cholesteatoma is an abnormal skin growth that can develop in the middle ear and mastoid process, often as a result of chronic ear infections. It can lead to the destruction of surrounding structures and may cause hearing loss, dizziness, and other complications. Bilateral cholesteatomas indicate that the condition affects both ears, which can complicate diagnosis and management. Patients may present with symptoms such as ear discharge, hearing impairment, and a sensation of fullness in the ear. Diagnosis typically involves a thorough clinical examination, audiometric testing, and imaging studies such as CT scans to assess the extent of the disease. Management often requires surgical intervention to remove the cholesteatoma and reconstruct the tympanic membrane, with follow-up care to monitor for recurrence. The unspecified nature of this code indicates that the specific characteristics of the cholesteatoma have not been detailed, which may affect treatment planning and coding accuracy.
Detailed notes on ear examinations, imaging results, and treatment plans.
Patients presenting with chronic ear infections, hearing loss, or post-surgical follow-up.
Ensure clear documentation of the extent of cholesteatoma and any associated complications.
Audiometric evaluations and hearing assessments.
Patients with hearing loss secondary to cholesteatoma.
Document the impact of cholesteatoma on hearing and any recommended interventions.
Performed for removal of cholesteatoma and reconstruction of the tympanic membrane.
Operative report detailing the procedure and findings.
Otolaryngology specialists should ensure comprehensive documentation of the surgical approach and post-operative care.
Common symptoms include ear discharge, hearing loss, a feeling of fullness in the ear, dizziness, and tinnitus. Patients may also experience complications related to the condition.
Diagnosis typically involves a clinical examination, audiometric testing, and imaging studies such as CT scans to assess the extent of the cholesteatoma.
